---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000106"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:45:17.771770+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Founder and CSO Steven Prestrelski resigns, becomes Senior Scientific Advisor at Xeris Biopharma

## Summary
- Steven Prestrelski, PhD, Founder and Chief Scientific Officer, resigned effective June 30, 2023.
- He entered a consulting agreement as Senior Scientific Advisor from July 1, 2023 to January 31, 2025.
- The consulting agreement covers predefined services; no further financial terms disclosed.
- Transition follows founder's departure from executive role but retention as advisor.

## SEC filing metadata
- accession: 0001867096-23-000106
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/0001867096-23-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000106/xers-20230628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000106
- JSON: https://secwatch.observer/filing/0001867096-23-000106.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.